References
- Henson PM. Cellular sources of platelet activating factor. Pharmacology of inflammation and allergy, F Russo-Marie, BB Vargaftig, J Benven-Iste. INSERM., Paris 1981; 63–81
- Chignard M, et al. The role of PAF in platelet aggregation. Nature 1979; 279: 779–880
- Doebber J W, Wu M S, Shen TY. Platelet-activating factor intravenous infusion in rat stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. Biochem Biophys Res Commun 1984; 125: 980–987
- Humphrey D M, et al. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest 1982; 46: 422–427
- Gonzalez-Crussi F, Hseuh W. Experimental model of ischemic bowel necrosis. The role of platelet activating factor and endotoxin. Am J Pathol 1983; 112: 127–135
- Rosam A-C, Wallace JL, Whittle B, JR. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 1986; 319: 54–56
- Sharon P, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638–640
- Sharon P, Stenson WF. Enhanced synthesis of leu-kotrien B4by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–460
- Mencia-Huerta J M, et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone-marrow-derived mast cells sensitized with monoclonal IgE. J Immunol 1983; 130: 2958–2964
- Roubin R, Benveniste J. Release of lipid mediators from macrophages and its pharmacological modulation. The reticuloendothelial system, JW Hadden, A Szentivanyi. Plenum, New York 1985; 73–96
- Billah M M, Bryant R W, Siegel MI. Lipoxygenase products of arachidonic acid modulate biosynthesis of platelet-activating factor (l-0-akyl-2-akyl-sn-glycero-3-phosphocholine). J Biol Chem 1985; 260: 6899–6906
- Stenson W F, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494–497